
Graphic depicting how new CDT nanoagent works.
Illustration Credit: Parinaz Ghanbari.
Scientific Frontline: "At a Glance" Summary
- Main Discovery: A novel iron-based metal-organic framework (MOF) nanoagent has been developed to trigger dual chemical reactions within cancer cells, generating oxidative stress via hydroxyl radicals and singlet oxygen to eradicate malignant cells while sparing healthy tissue.
- Methodology: The researchers designed a chemodynamic therapy (CDT) agent that leverages the acidic and high-hydrogen peroxide microenvironment of tumors to catalyze the simultaneous production of hydroxyl radicals and singlet oxygen.
- Key Data: In preclinical studies involving mice with human breast cancer, systemic administration of the nanoagent resulted in complete tumor eradication and long-term prevention of recurrence with no observed systemic toxicity or adverse effects on healthy cells.
- Significance: This advancement overcomes limitations of existing CDT agents that typically generate only one type of reactive oxygen species or lack sufficient catalytic activity, offering a more potent and durable therapeutic benefit for cancer treatment.
- Future Application: The team plans to evaluate the therapeutic efficacy of this nanoagent in various other cancer types, including aggressive pancreatic cancer, to establish its broad applicability prior to human clinical trials.
- Branch of Science: Nanomedicine, Oncology, and Pharmaceutical Sciences


.jpg)





.jpg)